TORONTO, June 5, 2026
Edesa Biotech, Inc. announced new exploratory analyses demonstrating positive clinical signals for paridiprubart (EB05), its first-in-class anti-TLR4 monoclonal antibody, in patients suffering from acute kidney injury (AKI) and respiratory distress. The findings, presented at the 63rd European Renal Association (ERA) Congress in Glasgow, Scotland, expand upon previously reported Phase 3 ARDS results and suggest that paridiprubart may provide meaningful clinical benefits in a high-risk patient population with significant unmet medical need.
Significant Improvements in Mortality and Kidney Outcomes
The new analysis evaluated a combined cohort of 101 patients with AKI and respiratory distress, incorporating participants from both Phase 2 and Phase 3 studies. Patients treated with paridiprubart plus standard of care demonstrated a 32% relative reduction in 28-day mortality, with adjusted mortality rates of 33% compared to 49% in the placebo group. The treatment also showed encouraging results on Major Adverse Kidney Events at 30 Days (MAKE30), reducing the incidence to 41% versus 53% with placebo, representing a 23% relative reduction. These findings indicate consistent benefits across both survival and kidney-specific clinical endpoints.
Strong Biological Rationale Supports Further Development
Paridiprubart targets Toll-like Receptor 4 (TLR4), a key driver of inflammatory responses involved in both lung and kidney injury. According to Edesa, the consistency of the observed benefits strengthens the hypothesis that inhibiting TLR4-mediated inflammation may help reduce multi-organ dysfunction in critically ill patients. The AKI subgroup represented a particularly severe patient population, with approximately 90% experiencing moderate-to-severe ARDS and nearly half requiring invasive mechanical ventilation or ECMO support, highlighting the significance of the observed clinical outcomes.
Advertisement
Favorable Safety Profile and Future Potential
The treatment was generally well tolerated, with low rates of adverse events, serious adverse events, and infections. No meaningful safety differences were observed between the paridiprubart and placebo groups, consistent with the favorable safety profile reported across more than 400 patients treated with paridiprubart in clinical studies to date. Edesa believes these exploratory findings support continued development of paridiprubart for ARDS while also providing a strong rationale for future clinical trials specifically focused on acute kidney injury, a condition for which no approved targeted pharmacological therapies currently exist.
Source: Edesa Biotech press release
